Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer
NCT ID: NCT04258657
Last Updated: 2020-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2020-03-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
NCT03137004
Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
NCT04258644
Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
NCT02229058
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NCT04047953
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT07098026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paclitaxel-albumin and S-1
paclitaxel-albumin and S-1
neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
paclitaxel-albumin and S-1
neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Type II and III esophageal-gastric-junction malignancy
3. AJCC stage II-III
4. No contraindications for surgery, radical resection can be expected
5. KPS\>60; ECOG score:0-2
6. Expactant survival period\>6 months
7. Age 20\~75
8. No other major health issues
9. Lab results within 7 days before inclusion must satisfy:
1. neutrophil≥1.5×109/L
2. PLT≥100×109/L
3. hemogloblin≥90g/L
4. ALT,AST\<1.5 upper limit
5. Tbil≤1.0×UNL
6. serum creatinine\<1.5×UNL
7. PT-INR/PTT\<1.7 upper limit
10. with measurable lesion according to RECIST1.1 criteria
11. with consent
12. co-operative
Exclusion Criteria
2. allergic to relevant drugs
3. experienced any other drug therapy with 4 weeks before inclusion
4. experienced any drug therapy for gastric cancer at anytime
5. diagnosed with any other malignancy within the past 5 years
6. women at child-bearing age; pregnant or breast-feeding women
7. with severe heart disease
8. with upper GI digestion or disrupted absorption
9. with peripheral neural disease
10. with transplated organs or organs having been resected for transplantation
11. known DPD deficiency
12. with uncontrolled infection
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhongtao Zhang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Deng
Role: STUDY_DIRECTOR
Beijing Friendship Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongtao Zhang
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BFH-GCCT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.